AstraZeneca: Cardiovascular Diseases trials

The registry lists 41 Cardiovascular Diseases studies with AstraZeneca as lead sponsor. 2 are open to participants now and 9 have results posted.

Phase 1 15Phase 2 2Phase 3 7Phase 4 1No phase 16(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First EventRecruitingNCT07000357Phase 3
• The Prevalence of COPD in Patients With Cardiovascular Disease and the Benefit of Cardiopulmonary Co-managementRecruitingNCT06909773Not applicable
• Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular DiseaseCompletedNCT03004638Phase 2Results posted
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male SubjectsCompletedNCT02632526Phase 1Results posted
• Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVRTerminatedNCT02227368Phase 2Results posted
• [E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROLCompletedNCT01408303Phase 3Results posted
• A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)CompletedNCT01347580Phase 4Results posted
• Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of AspirinCompletedNCT01225562Phase 3Results posted
• Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular DiseaseCompletedNCT01042977Phase 3Results posted
• Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and HypertensionCompletedNCT01031680Phase 3Results posted
• JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) EventsTerminatedNCT00239681Phase 3Results posted
• A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD EventActive, not recruitingNCT07000123Phase 3
• Non-interventional Study on Guideline Directed Medical Therapy for Patients With Heart Failure (HF) in GermanyActive, not recruitingNCT06675552
• Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in GermanyActive, not recruitingNCT06336330
• An ADME Study of [14C]AZD0780 in Healthy Male SubjectsCompletedNCT05817461Phase 1
• A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers.CompletedNCT05457270Phase 1
• A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With ItraconazoleCompletedNCT05236543Phase 1
• Study to Assess the Effect of AZD4831 on the Pharmacokinetics (Drug Behavior in the Body) of MidazolamCompletedNCT05052710Phase 1
• Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male SubjectsCompletedNCT04686591Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AZD3366 in Healthy Subjects, Japanese and Chinese SubjectsCompletedNCT04588727Phase 1
• A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy SubjectsCompletedNCT04492709Phase 1
• A Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolite Profile and Metabolite Identification of [14C]AZD4831CompletedNCT04407091Phase 1
• Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD5718 in VolunteersCompletedNCT03948451Phase 1
• Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes MellitusCompletedNCT03654313Phase 1
• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese MenCompletedNCT03400488Phase 1
• A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular DiseaseCompletedNCT03136991Phase 1
• A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male SubjectsTerminatedNCT02712372Phase 1
• A Study to Evaluate the Clinical Epidemiology of Patients With Heart Failure (HF) in IndiaWithdrawnNCT02047526
• Centralised Pan-Algerian Survey on the Undertreatment of HypercholesterolemiaCompletedNCT01768403
• A Study to Derive Normative Distribution of CIMT and to Determine Its Correlation With Cardiovascular Risk FactorsCompletedNCT01551875
• An Observational Study of Statin Treatment Induced HDL ChangesCompletedNCT01551784
• An Interaction Study to Evaluate the Effect of Esomeprazole/Acetylsalicylic Acid on the Metabolism and Effect of ClopidogrelCompletedNCT01210339Phase 1
• Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of HypertensionCompletedNCT01152567
• Study of Artery Conditions of 'At-risk' Asian People Not on Lipid-lowering DrugsCompletedNCT00970918Not applicable
• Audit and Screening Study to Determine the Prevalence of Peripheral Arterial DiseaseCompletedNCT00928629Not applicable
• Management of Cardiovascular Risk FactorsCompletedNCT00848380
• A Study on Intima Media Thickness (IMT) in Middle-aged SubjectsCompletedNCT00784264
• CARE - Quality Improvement in Cardiovascular Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.CompletedNCT00713960
• Prevalence of Peripheral Arterial Disease in Subject With a Moderate Risk of Cardiovascular (CV) Disease (CVD) in Primary PreventionCompletedNCT00689377
• An Observational Study of Burden of Upper GI-Symptoms in CV Risk PatientsCompletedNCT00681759
• Atacand (Candesartan) Real Life StudyCompletedNCT00620178